{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Cancers&page=51",
    "query": {
      "condition": "Non-small Cell Lung Cancers",
      "page": 51
    },
    "page_size": 10
  },
  "pagination": {
    "page": 51,
    "page_size": 10,
    "total_count": 3679,
    "total_pages": 368,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Cancers&page=52&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Cancers&page=50&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T12:21:14.127Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03520686",
      "title": "Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "NAI + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "NAI + Nivolumab + Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin + Nab-paclitaxel + Atezolizumab + NAI",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin and Nab-paclitaxel plus Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2018-05-18",
      "completion_date": "2025-10-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-10-25T12:21:14.127Z",
      "location_count": 31,
      "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 28 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03520686"
    },
    {
      "nct_id": "NCT03778229",
      "title": "Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma"
      ],
      "interventions": [
        {
          "name": "osimertinib",
          "type": "DRUG"
        },
        {
          "name": "savolitinib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 367,
      "start_date": "2019-01-09",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-10-25T12:21:14.127Z",
      "location_count": 11,
      "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 8 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03778229"
    },
    {
      "nct_id": "NCT04381494",
      "title": "Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Unresectable Stage III NSCLC"
      ],
      "interventions": [
        {
          "name": "Multiparametric Mobile Technology",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 40,
      "start_date": "2020-04-27",
      "completion_date": "2022-01-27",
      "has_results": true,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-10-25T12:21:14.127Z",
      "location_count": 18,
      "location_summary": "Long Beach, California • Santa Ana, California • Englewood, Colorado + 15 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Plainville",
          "state": "Connecticut"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04381494"
    },
    {
      "nct_id": "NCT00400829",
      "title": "E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Non-small Cell Lung Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IV Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "eribulin mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2006-11",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2015-01-07",
      "last_synced_at": "2026-10-25T12:21:14.127Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00400829"
    },
    {
      "nct_id": "NCT00900302",
      "title": "OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "Up to 120 Years"
      },
      "enrollment_count": 98,
      "start_date": "2005-04",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2016-02-10",
      "last_synced_at": "2026-10-25T12:21:14.127Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00900302"
    },
    {
      "nct_id": "NCT00004253",
      "title": "Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Baptist Health South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-10-25T12:21:14.127Z",
      "location_count": 2,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004253"
    },
    {
      "nct_id": "NCT07229339",
      "title": "Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Non-Squamous Non-Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Zipalertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2027-06-01",
      "completion_date": "2030-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-10-25T12:21:14.127Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07229339"
    },
    {
      "nct_id": "NCT03050554",
      "title": "SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Early Stage Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "SBRT",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Andrew Sharabi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2017-10-26",
      "completion_date": "2019-10-07",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-10-25T12:21:14.127Z",
      "location_count": 2,
      "location_summary": "La Jolla, California • Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03050554"
    },
    {
      "nct_id": "NCT01703481",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumor or Lymphoma"
      ],
      "interventions": [
        {
          "name": "JNJ-42756493: Part 1",
          "type": "DRUG"
        },
        {
          "name": "JNJ-42756493: Part 2",
          "type": "DRUG"
        },
        {
          "name": "JNJ-42756493: Part 3",
          "type": "DRUG"
        },
        {
          "name": "JNJ-42756493: Part 4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 188,
      "start_date": "2012-06-15",
      "completion_date": "2017-07-05",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-10-25T12:21:14.127Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01703481"
    },
    {
      "nct_id": "NCT06585488",
      "title": "A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumors",
        "Advanced Non-squamous Non-small-cell Lung Cancer",
        "Advanced Colorectal Cancer",
        "Advanced Pancreatic Ductal Adenocarcinoma",
        "Advanced Gastric Cancer",
        "Advanced Gastroesophageal Junction Cancer",
        "Advanced Esophageal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "BGB-53038",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BeOne Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2024-12-13",
      "completion_date": "2026-04-23",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-10-25T12:21:14.127Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06585488"
    }
  ]
}